Clinical Trials

Trials & Sites

Proacta is currently conducting Phase I and Phase II trials with PR-104. For additional information on Proacta clinical trial status please visit http://www.cancer.gov/clinicaltrials

Study PR-104-1001: A Phase I, Multi-Center, Open Label, Dose Escalation Trial of the Safety and Pharmacokinetics of Intravenous PR-104 Given Every 3 Weeks in Patients with Solid Tumors.

This study was designed to find the correct dose of PR-104 when it is given once every three weeks to patients with various types of cancer. The study also helped determine the type of side effects that can be expected with PR-104. This study was initiated in 2006 at clinical sites in the US, New Zealand, and Australia, and has now been completed.

PR-104-1002: A Phase I, Multi-Center, Open-Label, Dose Escalation Trial of the Safety and Pharmacokinetics of Intravenous PR-104 Given Weekly in Subjects with Solid Tumors.

This study is designed to find the correct dose of PR-104 when it is given every week to patients with various types of cancer. The study will also help determine the type of side effects that can be expected with PR-104. The study is open at a limited number of clinical sites in the US, New Zealand, and Australia. The study started in February 2007.

PR-104-1003: A Phase Ib, Multi-Center, Open Label, Dose Escalation Trial of Intravenous PR-104 Given in Combination with Docetaxel or Gemcitabine in Subjects with Solid Tumors

This study is designed to find the correct dose of PR-104 when it is given along with either docetaxel or with gemcitabine. Both docetaxel and gemcitabine are approved cancer drugs that are used commonly to treat many different types of cancer. The study is open at a limited number of clinical sites in the US and New Zealand. The study started in March 2007.

PR-104-1004: A Phase Ib, Multi-Center, Open Label, Dose Escalation Trial of Intravenous PR-104 Given in Combination with G-CSF in Subjects with Solid Tumors

This study uses G-CSF (granulocyte-colony stimulating factor) to protect subjects against potential neutropenia that can develop during administration of PR-104. The study is open at a limited number of clinical sites in the US. The study started in February 2008.

PR-104-2001: A Phase II, Multi-Center, Open-Label, Trial of PR-104 in Treatment Naïve and Sensitive-relapse Small Cell Lung Cancer

This study is designed to test the activity of PR-104 alone in patients who have been diagnosed with a specific type of lung cancer known as Small Cell Lung Cancer. The study will open at several clinical sites in the United States and started in January 2008.